Prenylamine-induced ventricular tachycardia and syncope controlled by ventricular pacing

E GRENA DIER, S KEIDAR, G ALPAN, A MARMOR, A PALANT

From the Department of Cardiology, Lady Davis Carmel Hospital, Haifa, Israel

SUMMARY We describe eight patients treated for angina with prenylamine who developed life-threatening ventricular arrhythmias after QT interval prolongation. When prenylamine administration was stopped QT interval shortened to within normal values, while the ventricular arrhythmias were controlled by a temporary ventricular pacemaker and disappeared after several days. We stress the importance of surveillance of the QT interval and ventricular arrhythmias in patients receiving long-term treatment with prenylamine.

Since its introduction as an antianginal agent, prenylamine has been shown to have a wide margin of therapeutic safety. Indeed very few life-threatening complications of prenylamine treatment have been reported. Thus the association of ventricular arrhythmias with prenylamine is of some interest, especially in view of the fact that it can be anticipated and thus avoided.

We report on the mode of treatment of eight patients with prolonged QT intervals and serious symptomatic ventricular tachyarrhythmias caused by prenylamine.

Patients and results

The eight patients constituting this group were admitted to the Department of Cardiology at the Lady Davis Carmel Hospital because of several episodes of syncope in the few weeks preceding admission.

They had coronary artery disease with mild anginal syndrome and were on a regimen of prenylamine 180 to 240 mg/day for at least two months before being admitted to hospital. Clinical details and additional drugs are summarised in the Table.

On arrival all patients had electrocardiograms showing prolonged QT interval, ventricular premature beats, and short runs of ventricular tachycardia with torsade de pointes pattern (Fig. 1–4).

In the first four patients treatment with lino-

caine was initiated immediately; this failed, however, to control the arrhythmia. Moreover, two patients (cases 1 and 3) developed transient Mobitz second and third degree atrioventricular block on being given a 100 mg bolus of intravenous lino-

Table Clinical, laboratory, and electrocardiographic data of patients on prenylamine with torsade de pointes

<table>
<thead>
<tr>
<th>Case</th>
<th>Age</th>
<th>Sex</th>
<th>Additional drugs</th>
<th>No. of syncope attacks</th>
<th>Duration of symptoms (wk)</th>
<th>Heart rate on admission (s)</th>
<th>QT on admission (s)</th>
<th>QTc on discharge (mg/100 ml)</th>
<th>Serum electrolytes (mg/100 ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>76</td>
<td>F</td>
<td>+</td>
<td>6</td>
<td>8</td>
<td>0.58</td>
<td>0.61</td>
<td>0.37</td>
<td>2.3 9.1 4.9</td>
</tr>
<tr>
<td>2</td>
<td>62</td>
<td>F</td>
<td>+</td>
<td>2</td>
<td>4</td>
<td>0.60</td>
<td>0.78</td>
<td>0.42</td>
<td>1.8 9.0 4.0</td>
</tr>
<tr>
<td>3</td>
<td>64</td>
<td>M</td>
<td>0.25 +</td>
<td>10</td>
<td>5</td>
<td>0.64</td>
<td>0.64</td>
<td>0.32</td>
<td>1.9 11.3 4.0</td>
</tr>
<tr>
<td>4</td>
<td>72</td>
<td>F</td>
<td>+</td>
<td>3</td>
<td>5</td>
<td>0.60</td>
<td>0.67</td>
<td>0.36</td>
<td>2.2 11.7 5.3</td>
</tr>
<tr>
<td>5</td>
<td>67</td>
<td>F</td>
<td>+</td>
<td>4</td>
<td>10</td>
<td>0.66</td>
<td>0.66</td>
<td>0.41</td>
<td>2.1 9.0 4.6</td>
</tr>
<tr>
<td>6</td>
<td>64</td>
<td>M</td>
<td>+</td>
<td>2</td>
<td>3</td>
<td>0.53</td>
<td>0.56</td>
<td>0.42</td>
<td>2.2 10.7 5.1</td>
</tr>
<tr>
<td>7</td>
<td>74</td>
<td>F</td>
<td>+</td>
<td>1</td>
<td>1</td>
<td>0.56</td>
<td>0.52</td>
<td>0.39</td>
<td>2.0 10.1 4.7</td>
</tr>
<tr>
<td>8</td>
<td>84</td>
<td>F</td>
<td>+</td>
<td>80</td>
<td>7</td>
<td>0.64</td>
<td>0.70</td>
<td>0.43</td>
<td>1.9 9.0 3.9</td>
</tr>
</tbody>
</table>

QTc was calculated according to the formula of Bazett: 

\[ QTc = \frac{QT}{\sqrt{R-R}} \]
Prenylamine-induced ventricular tachycardia

Fig. 1 (a) Ventricular tachycardia showing torsade de pointes (lead II, case 1). (b) Ventricular tachycardia showing torsade de pointes (lead V1, case 1).

Fig. 2 (a) Ventricular tachycardia showing torsade de pointes (lead II, case 4). (b) Ventricular tachycardia showing torsade de pointes (praeordial lead V1, case 4).

caine (Fig. 5). These four patients were treated by rapid ventricular pacing (100 pulses per minute) which proved to be effective in suppressing the ventricular arrhythmia. In view of the failure of lignocaine to control the arrhythmia and also the development of atrioventricular block in two patients, we treated the following four patients presenting to us by rapid ventricular pacing without attempting to initiate treatment with lignocaine. The arrhythmia was controlled successfully by this treatment.

The prolonged QT intervals returned to normal
Fig. 3 Ventricular tachycardia showing torsade de pointes (praecordial lead V1, case 3).

Fig. 4 Ventricular tachycardia showing torsade de pointes (monitor lead, case 8).

Fig. 5 Complete atrioventricular block after 100 mg intravenous bolus of lignocaine. Thirteen P waves with one ventricular escape beat (praecordial lead V1, case 3).

Fig. 6 Prolonged QT interval 0.64 s (QTc = 0.7) on admission and after a few days (lead aVL, case 8).

values in all eight patients with concomitant cessation of the ventricular arrhythmias two to four days after prenylamine was discontinued (Fig. 6).

On admission none of these patients had clinical, electrocardiographic, or enzymatic signs of myocardial ischaemia or infarction. Serum potassium, magnesium, and calcium (Table) were within the normal range of values.

In addition, all the first and second degree relatives of our patients were examined and none was found to have prolongation of the QT interval on the electrocardiogram or a history of syncope.

**Comment**

Much is known about the pharmacological action of prenylamine but the exact mechanism of its antianginal action is still uncertain. It seems probable that this is largely a result of inhibition of cathecholamine uptake by the storage granules. It is known that intravenous prenylamine produces coronary vasodilatation and an increase in coronary blood flow. Prenylamine is also known to delay calcium transport in the sarcoplasmic reticulum and its antianginal effect is caused in part by its effect on electromechanical coupling. It is known to have a large number of side effects including sedation, gastrointestinal symptoms, and skin reactions. Recently, a new complication has been described which includes prolongation of the QT interval and ventricular tachycardia with syncopal attacks.

QT prolongation may be a result of ischaemic heart disease, hypokalaemia, hypocalcaemia, hypomagnesaemia, several antiarrhythmic drugs,
Prenylamine-induced ventricular tachycardia

333
treatment with phenothiazines and tricyclic compounds, liquid protein diets, and is a feature of the Jervell-Lange-Nielsen and the Romano-Ward syndromes. QT prolongation encourages re-entry processes and ventricular arrhythmias including torsade de pointes. Torsade de pointes may also arise during slow heart rhythm as an escape mechanism in sinus node dysfunction and atrioventricular block. It has also been reported in a neonate with myocarditis and as a rare complication of ventricular pacing.

In the eight cases described above we wish to draw attention to the prolongation of the QT interval induced by prenylamine, which was followed by torsade de pointes. The effects were reversible and controlled by ventricular pacing. All eight patients were examined echocardiographically and phonocardiographically and none was found to have prolapse of the mitral valve or any myocardopathy detectable by these tests. In all cases the prolonged QT intervals returned to normal values within several days after withdrawal of prenylamine, with the concomitant disappearance of the ventricular arrhythmias. Neither syncope nor palpitation has occurred in any of our patients on follow-up, and none has shown conduction disorders or arrhythmias.

The occurrence of atrioventricular block after an intravenous bolus of lignocaine is of some interest. The drug normally asserts minimal effects on the cardiac conducting system, and heart block induced by lignocaine is a rare complication. Thus the induction of atrioventricular block in two patients of four to whom lignocaine was given is a source of some misgiving. Though unconfirmed, we cannot discount the possibility that at least in some cases lignocaine may be inadvisable in torsade de pointes.

The confident diagnosis of torsade de pointes requires the simultaneous recording of three leads; not every run of ventricular extrasystoles which change shape can be given this label. In view of the urgency of the situation we recorded only two leads (Fig. 1 and 2).

Torsade de pointes can be treated either by intravenous isoprenaline infusion or by pacing. Since the aetiology of the arrhythmia in our patients was secondary to prenylamine and there was a presumed risk of recurrence until serum levels of the drug would have fallen, we chose pacing, wishing to avoid the possible hazards of prolonged or repeated intravenous isoprenaline, especially in patients with angina.

We advise routine electrocardiographic observations in patients on prenylamine. Particular attention should be paid to the appearance of new albeit mild ventricular arrhythmias and prolongation of the QT interval, which may be the harbingers of life-threatening torsade de pointes.

References
18 Jervell A, Lange-Nielsen F. Congenital deaf-mutism


Requests for reprints to Dr A Palant, Department of Cardiology, Lady Davis Carmel Hospital, POB 7222, Haifa, Israel.
Prenylamine-induced ventricular tachycardia and syncope controlled by ventricular pacing.
E Grenadier, S Keidar, G Alpan, A Marmor and A Palant

Br Heart J 1980 44: 330-334
doi: 10.1136/hrt.44.3.330

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/